Development Plan Reporting. Telix will provide Lilly with [**] written updates detailing the progress of activities under the Development Plan (including but not limited to the POC Study) and the results thereof. In addition, within [**] of completion of any pre- clinical (animal) studies set forth in the Development Plan, which is expected to occur within [**] after the Effective Date, and completion of the POC Study, respectively, Telix will provide a report detailing the results of such pre-clinical studies or POC Study, respectively, to Lilly.
Development Plan Reporting. 1888 shall deliver to Cielo upon the execution of this License Agreement, or as otherwise agreed, and maintain at all material times an updated plan of development of the Licensed Assets in a form acceptable to Cielo, and shall provide regular reports, no less frequently than once per quarter, in connection with Development and Improvement of the Licensed Assets and Licensed Technology. Until the 1st commercial plant is in operations, these reports may be provided verbally.
Development Plan Reporting. G&W’s initial outline of its Development Plan for the Selected Compound and Licensed Products shall be provided to Liquidia within sixty (60) days after the Effective Date. G&W shall provide Liquidia with an updated Development Plan within twelve (12) months through the JSC following the Effective Date, and shall update the Development Plan at least annually. At each JSC meeting, G&W and Liquidia shall discuss G&W’s progress under the Development Plan in a sufficient level of detail to permit Liquidia to assess G&W’s compliance with its diligence obligations under Section 4.1.
Development Plan Reporting. Novo Nordisk shall provide XOMA with an initial [*] development plan for the Licensed Antibodies and Licensed Products within sixty (60) days of the Effective Date. Novo Nordisk shall provide XOMA with written reports [*] relating to the activities of Novo Nordisk, its Affiliates and sublicensees with respect to the Development of Licensed Antibodies and Licensed Products in the Field in the Territory, both as to activities conducted during the prior reporting period and planned activities, on a Licensed Antibody-by-Licensed Antibody, Licensed Product-by-Licensed Product and Indication-by-Indication basis, in sufficient depth to enable XOMA to reasonably assess Novo Nordisk’s compliance with Section 3.1. Novo Nordisk shall present such report to XOMA in conjunction with a meeting (either in person or by videoconference, as the Parties may agree) with XOMA and Novo Nordisk’s personnel responsible for the conduct of such Development, which personnel shall include at least [*]. Such updates shall occur [*] per year until such time as [*], and [*] thereafter.
